88% of patients with asthma and nasal polyps achieve dual remission on dupilumab

This study looked at 28 adults with both severe asthma and chronic sinusitis with nasal polyps who were treated with dupilumab for 24 months. The goal was to see if the drug could help control both conditions at the same time, called 'dual remission.' After 24 months, 88% of patients achieved dual remission, meaning their asthma and nasal polyps were well-controlled without needing oral steroids. However, only 32% fully recovered their sense of smell, suggesting that while the drug is very effective, smell recovery remains a challenge.